Patent US3965089A successfully refreshed from Google Patents.
US3965089A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Process for the production of a cyclic ureido-derivative of a deoxystreptamine-containing antibiotic and products thereof
Assignee: Microbial Chemistry Research Foundation
•
Filing: 1973-03-12
•
Granted: 1976-06-22
•
Expires: 1993-03-12
Abstract
Abstract A new cyclic ureido-derivative of a deoxystreptamine-containing antibiotic represented by the general formula: ##SPC1## Wherein R a , R b and R c stand for the residues present in the molecule of said antibiotic other than the deoxystreptamine moiety thereof is produced.
Inventors
- 👤 Hamao Umezawa
- 👤 Kenji Maeda
- 👤 Shinichi Kondo
- 👤 Shunzo Fukatsu
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-31 08:01
CPC Classifications
C; C07; C07H; C07H17/00; C07H17/02; C07H15/00; C07H15/20; C07H15/22; C07H15/222
Claims Analysis
Total Claims: 24
Claim 1
Independent Claim
53 words
The cyclic ureido-derivative of a deoxystreptamine-containing antibiotic of the formula: ##SPC19## wherein R a is an aminoglycoside present in the molecule other than on the deoxystreptamine moiety thereof, R b and R c are each hydrogen or an aminoglycoside present in the molecule of the antibiotic other than on the deoxystreptamine moiety thereof.
Claim 2
Dependent Claim
53 words
The cyclic ureido-derivative of a deoxystreptamine-containing antibiotic of the formula: ##SPC19## wherein R a is an aminoglycoside present in the molecule other than on the deoxystreptamine moiety thereof, R b and R c are each hydrogen or an aminoglycoside present in the molecule of the antibiotic other than on the deoxystreptamine moiety thereof.
Claim 3
Dependent Claim
17 words
A compound according to claim 1, wherein one of R b and R c is an aminoglycoside.
Claim 4
Dependent Claim
15 words
A compound according to claim 1, wherein R b and R c are both hydrogen.
Claim 5
Dependent Claim
42 words
A compound according to claim 1, wherein said antibiotic is selected from the group consisting of kanamycin A, kanamycin B, kanamycin C, neamine, neomycin B, neomycin C, paromamine, paromomycin I, paromomycin II, ribostamycin, lividomycin A, lividomycin B, gentamicin A and gentamicin C.
Claim 6
Dependent Claim
26 words
A compound according to claim 4, wherein said antibiotic is selected from the group consisting of kanamycin A, kanamycin B, kanamycin C, neamime, paromamine and ribostamycin.
Claim 7
Dependent Claim
11 words
The cyclic ureido-derivative of kanamycin A represented by the formula: ##SPC20##
Claim 8
Dependent Claim
11 words
The cyclic ureido-derivative of kanamycin A represented by the formula: ##SPC20##
Claim 9
Dependent Claim
11 words
The cyclic ureido-derivative of kanamycin B represented by the formula: ##SPC21##
Claim 10
Dependent Claim
11 words
The cyclic ureido-derivative of kanamycin B represented by the formula: ##SPC21##
Claim 11
Dependent Claim
10 words
The cyclic ureido-derivative of neamine represented by the formula: ##SPC22##
Claim 12
Dependent Claim
10 words
The cyclic ureido-derivative of neamine represented by the formula: ##SPC22##
Claim 13
Dependent Claim
10 words
The cyclic ureido-derivative of paromamine represented by the formula: ##SPC23##
Claim 14
Dependent Claim
10 words
The cyclic ureido-derivative of paromamine represented by the formula: ##SPC23##
Claim 15
Dependent Claim
10 words
The cyclic ureido-derivative of ribostamycin represented by the formula: ##SPC24##
Claim 16
Dependent Claim
10 words
The cyclic ureido-derivative of ribostamycin represented by the formula: ##SPC24##
Claim 17
Dependent Claim
222 words
A process for the production of cyclic ureido-deoxystreptamine-containing antibiotics of the formula: ##SPC25## wherein R a is an aminoglycoside present in the molecule of the antibiotic other than on the deoxystreptamine moiety thereof and R b and R c are each hydrogen or an aminoglycoside present in the molecule of said antibiotic other than on the deoxystreptamine moiety thereof, which comprises reacting in an inert solvent: (a) an alkali metal base or an alkaline earth metal base in an amount sufficient to provide an alkaline reaction mixture, with (b) a urethane derivative of said antibiotic of the formula: ##SPC26## wherein R 1 , R 2 and R 3 are each amino-protected derivatives of R a , R b and and R c , respectively in which all of the aminoglycoside groups originally present therein are substituted with an amino-protecting group of the formula --CO--OR 4 wherein R 4 is alkyl of 1-5 carbon atoms, alkenyl of 2-5 carbon atoms, aralkyl, cycloalkyl, aryl or a monovalent heterocyclic group, to: i. convert the two protected amino groups --NH--CO --OR 4 in the deoxystreptamine moiety of said urethane derivative into the cyclic ureido form, and simultaneously ii. liberate said amino-protecting groups from R 1 , R 2 and R 3 whereby the aminoglycoside members of R a , R b and R c are regenerated.
Claim 18
Dependent Claim
222 words
A process for the production of cyclic ureido-deoxystreptamine-containing antibiotics of the formula: ##SPC25## wherein R a is an aminoglycoside present in the molecule of the antibiotic other than on the deoxystreptamine moiety thereof and R b and R c are each hydrogen or an aminoglycoside present in the molecule of said antibiotic other than on the deoxystreptamine moiety thereof, which comprises reacting in an inert solvent: (a) an alkali metal base or an alkaline earth metal base in an amount sufficient to provide an alkaline reaction mixture, with (b) a urethane derivative of said antibiotic of the formula: ##SPC26## wherein R 1 , R 2 and R 3 are each amino-protected derivatives of R a , R b and and R c , respectively in which all of the aminoglycoside groups originally present therein are substituted with an amino-protecting group of the formula --CO--OR 4 wherein R 4 is alkyl of 1-5 carbon atoms, alkenyl of 2-5 carbon atoms, aralkyl, cycloalkyl, aryl or a monovalent heterocyclic group, to: i. convert the two protected amino groups --NH--CO --OR 4 in the deoxystreptamine moiety of said urethane derivative into the cyclic ureido form, and simultaneously ii. liberate said amino-protecting groups from R 1 , R 2 and R 3 whereby the aminoglycoside members of R a , R b and R c are regenerated.
Claim 19
Dependent Claim
47 words
A process according to claim 11, wherein the deoxstreptamine-containing antibiotic is selected from the group consisting of cyclic ureido derivatives of kanamycin A, kanamycin B, kanamycin C, neamine, neomycin B, neomycin C, paromamine, paromomycin I, paromomycin II, ribostamycin, lividomycin A, lividomycin B, gentamicin A and gentamicin C.
Claim 20
Dependent Claim
27 words
A process according to claim 12, wherein the deoxystreptamine-containing antibiotic is selected from the group consisting of kanamycin A, kanamycin B, kanamycin C, neamine, paromamine and ribostamycin.
Claim 21
Dependent Claim
26 words
A process according to claim 11, wherein R 4 is alkyl of 1-5 carbon atoms, alkenyl of 2.5 carbon atoms, cyclopentyl, phenyl, benzyl, p-nitrobenzyl or furfuryl.
Claim 22
Dependent Claim
12 words
A process according to claim 13, wherein said base is barium hydroxide.
Claim 23
Dependent Claim
117 words
A process according to claim 11, in which the deoxystreptamine-containing antibiotic is selected from the group consisting of cyclic ureido derivatives of kanamycin A, kanamycin B, kanamycin C, neamine, neomycin B, neomycin C, paromamine, paromomycin I, paromomycin II, ribostamycin, lividomycin A, lividomycin B, gentamicin A and gentamicin C, further comprising preparing said urethane derivative by reacting said antibiotic with a member selected from the group consisting of a chloroformate of the formula Cl--CO--OR 4 , a nitrophenyl carbonic acid ester of the formula p-NO 2 --C 6 H 5 -O--CO--R 4 , an N-hydroxysuccinimide carbonic acid ester of the formula: ##SPC27## an azidoformate of the formula N 3 --CO--OR 4 wherein R 4 has the above-indicated values.
Claim 24
Dependent Claim
21 words
A process according to claim 16, wherein said urethane derivatives are prepared in a reaction mixture containing an acid binding agent.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1979-06-22 | 1979-12-22 | 1980-06-22 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1983-06-22 | 1983-12-22 | 1984-06-22 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1987-06-22 | 1987-12-22 | 1988-06-22 | $7700.00 | Window Closed / Lapsed |